Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(17/week)
Canada
(12/week)
Haiti
(0/week)
Honduras
(0/week)
Jamaica
(0/week)
View all
(29/week)
News
United States
(1301/week)
Manufacturing
(724/week)
Energy
(519/week)
Technology
(1265/week)
Other Manufacturing
(494/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Johnson & Johnson
Jul 22, 2024
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
Jul 02, 2024
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
Jun 28, 2024
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
Jun 20, 2024
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction
Jun 17, 2024
Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
Jun 03, 2024
TECVAYLI® (teclistamab-cqyv) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma
Jun 03, 2024
DARZALEX® (daratumumab)-based regimens significantly improve clinical outcomes in both transplant-eligible and -ineligible patients who are newly diagnosed with multiple myeloma
May 29, 2024
Johnson & Johnson pivotal study of seltorexant shows statistically significant and clinically meaningful improvement in depressive symptoms and sleep disturbance outcomes
May 21, 2024
TREMFYA® (guselkumab) demonstrates superiority versus STELARA® (ustekinumab) in Phase 3 Crohn's disease program
May 05, 2024
TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively
May 03, 2024
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer
May 03, 2024
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery
May 01, 2024
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn's disease
Apr 11, 2024
Unique molecular properties of nipocalimab enabling differentiated potential in treating generalized myasthenia gravis to be presented at American Academy of Neurology's 2024 Annual Meeting
Apr 08, 2024
Findings Presented at ACC.24 Showed XARELTO® (rivaroxaban) Reduced the Risk of Clinically Significant Bleeding and Net Adverse Clinical Events or Rehospitalization
Apr 04, 2024
Johnson & Johnson to Showcase its Broad Scientific Leadership and Latest Innovations to Combat Cardiovascular Disease at ACC.24
Mar 22, 2024
U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)
Mar 21, 2024
Trial Library Announces Expansion of Collaboration to Advance Equity and Access in Oncology Clinical Trials
Mar 18, 2024
RYBREVANT® (amivantamab-vmjw) data at ELCC advance Johnson & Johnson's ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer
Mar 11, 2024
Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis
Page 1
››
Latest News
Jul 27, 2024
LuxCreo Expands Partnership with ASICS to Make Personalized Shoes Accessible to Everyone
Jul 27, 2024
Smith Foundry Shutting Down Minnesota Facility
Jul 27, 2024
Fonon Corporation Quartz Laser Welding Benefits Glass Manufacturers
Jul 27, 2024
Pioneer Power Announces Filing of Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2023
Jul 27, 2024
Philippines says 'no incidents' as it resupplies hotspot reef
Jul 27, 2024
Alliance Resource Partners, L.P. Declares Quarterly Distribution of $0.70 Per Unit; Announces Robinson...
Jul 27, 2024
EnerSys Completes Acquisition Of Bren-Tronics To Expand Presence In Critical Defense Applications
Jul 27, 2024
Warrior Announces Regular Quarterly Cash Dividend
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
View All Events